Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer

被引:30
作者
Kraunz, KS
Nelson, HH
Lemos, M
Godleski, JJ
Wiencke, JK
Kelsey, KT
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Dept Neurol Surg, Lab Mol Epidemiol, San Francisco, CA USA
关键词
p16(INK4a); homozygous deletion; mutation; tobacco; NSCLC;
D O I
10.1002/ijc.21522
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of p16(INK4a) in the Rb pathway is among the most common somatic alterations observed in nonsmall cell lung cancers (NSCLCs). While epigenetic inactivation of the p16(INK4a) gene promoter has been shown to be associated with increased tobacco carcinogen exposure, little investigation of any similar association of homozygous deletion or mutation of p16(INK4a) and tobacco use has been completed. In 177 consecutive NSCLCs, we examined the determinants of p16(INKa) homozygous deletion and mutation, including the pattern of tobacco smoking and asbestos exposure. We observed that p16(INK4a) homozygous deletion occurred at a higher frequency in never smokers as compared to former and current smokers (p = 0.01). This observation suggested that tumors from these patients might be more prone to DNA deletion events; consistent with this, epigenetic silencing of the DNA double-strand break repair genes FancF and BRCA1 was also associated with homozygous deletion of p16(INK4a) (p = 0.002 and p = 0.06, respectively). Finally, mutation of p16(INKa) was rare and only occurred in patients who were smokers. Hence, the character of somatic alteration in the Rb pathway (deletion, mutation or methylation silencing) in NSCLC is associated with the pattern of tobacco exposure, suggesting that susceptibility to lung cancer is, at least in part, mediated by the biological mechanism that selects for the character of the induced somatic lesion. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:1364 / 1369
页数:6
相关论文
共 34 条
[1]   ABERRATIONS OF P16(INK4) AND RETINOBLASTOMA TUMOR-SUPPRESSOR GENES OCCUR IN DISTINCT SUB-SETS OF HUMAN CANCER CELL-LINES [J].
AAGAARD, L ;
LUKAS, J ;
BARTKOVA, J ;
KJERULFF, AA ;
STRAUSS, M ;
BARTEK, J .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (01) :115-120
[2]   Epidemiology of lung cancer: Looking to the future [J].
Alberg, AJ ;
Brock, MV ;
Samet, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3175-3185
[3]  
Belinsky SA, 2002, CANCER RES, V62, P2370
[4]   Early detection of lung cancer: role of biomarkers [J].
Brambilla, C ;
Fievet, F ;
Jeanmart, M ;
de Fraipont, F ;
Lantuejoul, S ;
Frappat, V ;
Ferretti, G ;
Brichon, PY ;
Moro-Sibilot, D .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 :36S-44S
[5]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[6]   INK4A/ARF deletions are acquired at relapse in childhood acute lymphoblastic leukaemia:: a paired study on 25 patients using real-time polymerase chain reaction [J].
Carter, TL ;
Reaman, GH ;
Kees, UR .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :323-328
[7]   INCREASED MUTAGEN SENSITIVITY IN HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA PATIENTS, PARTICULARLY THOSE WITH MULTIPLE PRIMARY TUMORS [J].
CLOOS, J ;
BRAAKHUIS, BJM ;
STEEN, I ;
COPPER, MP ;
DEVRIES, N ;
NAUTA, JJP ;
SNOW, GB .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (06) :816-819
[8]   Genotoxic effects of asbestos in humans [J].
Dusinská, M ;
Collins, A ;
Kazimírová, A ;
Barancoková, M ;
Harrington, V ;
Volkovová, K ;
Staruchová, M ;
Horská, A ;
Wsólová, L ;
Kocan, A ;
Petrík, J ;
Machata, M ;
Ratcliffe, B ;
Kyrtopoulos, S .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2004, 553 (1-2) :91-102
[9]   Mechanisms of p16INK4A inactivation in non small-cell lung cancers [J].
Gazzeri, S ;
Gouyer, V ;
Vourc'h, C ;
Brambilla, C ;
Brambilla, E .
ONCOGENE, 1998, 16 (04) :497-504
[10]  
Geradts J, 1999, CLIN CANCER RES, V5, P791